Indeed, serum TGF-β1 levels have been shown to correlate with tumor burden, metastasis, and serum PSA in PCa patients and an increased level of TGF-β1 is strongly associated with PCa progression and poor clinical outcome [13, 14]. Here, TGFB1 is linked to posterior cortical atrophy.